Author Correction: A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Author Correction: A First-in-Class Selective EGFR and PI3K Inhibitor Enables Single-Molecule Targeting of Adaptive Resistance

  • By

  • Christopher E. Whitehead

  • Elizabeth K. Ziemke

  • Christy L. Frankowski-McGregor

  • Rachel A. Mumby

  • June Chung

  • Jinju Li

  • Nathaniel Osher

  • Oluwadara Coker

  • Veerabhadran Baladandayuthapani

  • Scott Kopetz

  • Judith S. Sebolt-Leopold

  • October 12, 2026

Share

  • 1

    Nature Cancer published the correction online on July 11, 2024.

  • 2

    A clerical error occurred while insulin ELISA values from mouse serum were transferred from the plate reader’s original data file.

  • 3

    The error caused three measurements to be duplicated in Fig. 6b and its associated source data file.

  • 4

    The underlying experiment used samples obtained from six mice.

  • 5

    Fig. 6b and its accompanying source data file were amended to show the full set of original measurements.

Original Source(s)

Author Correction: A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance

  • by Christopher E. Whitehead, Elizabeth K. Ziemke, Christy L. Frankowski-McGregor, Rachel A. Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Scott Kopetz, Judith S. Sebolt-Leopold

  • October 12, 2026

Related Content

Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors: A Secondary

The association between MGMT expression and outcome in H3 G34-mutant diffuse hemispheric glioma is robust to adjustment for pre-analytic and technical variables

2026 ASCO Breast Cancer Highlights: persevERA

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the persevERA trial and oral SERDS in metastatic breast cancer.

  • October 15, 2026

  • 1 min